• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

The 23-Valent Pneumoccocal (Pneumovax) Vaccine: For Which Patients?

Poll

For which of these patients would you give the 23-valent pneumoccocal vaccine?

Which of the following should get the 23-valent pneumoccocal (Pneumovax) vaccine per the Advisory Committee on Immunization Practices (ACIP) guidelines?

19-year-old who smokes a pack a day
16-year-old with diabetes mellitus
70-year-old who previously received a dose at age 64
All of the above
Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning / Image credit: ©MargJohnsonVA/AdobeStock

FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning

Sydney Jennings
January 8th 2025
Article

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Sanofi and SK Bioscience Expand Pneumococcal Vaccine Partnership, Launch Phase 3 Trial for PCV21 / Image credit: ©Crystal Light/AdobeStock

Sanofi and SK Bioscience Expand Pneumococcal Vaccine Partnership, Launch Phase 3 Trial for PCV21

Sydney Jennings
January 6th 2025
Article

Sanofi and SK bioscience expand collaboration on pneumococcal conjugate vaccines, including a 21-valent candidate for pediatric populations.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Online UTI Myths Found Common, Dangerous: Daily Dose/ image credit: ©New Africa/AdobeStock

Online UTI Myths Found Common, Dangerous: Daily Dose

Sydney Jennings
December 10th 2024
Article

Your daily dose of the clinical news you may have missed.

Influenza Antiviral Treatment Underutilized Among Vulnerable Youth: Daily Dose / image credit: ©New Africa/AdobeStock

Influenza Antiviral Treatment Underutilized Among Vulnerable Youth: Daily Dose

Sydney Jennings
December 6th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.